Can Fite Biopharma Ltd (NASDAQ:CANF) has been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Analysts have set a 1-year consensus price objective of $7.50 for the company and are expecting that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also assigned Can Fite Biopharma an industry rank of 100 out of 265 based on the ratings given to its competitors.

A number of research analysts recently weighed in on the stock. Maxim Group reissued a “buy” rating and set a $7.00 price target on shares of Can Fite Biopharma in a research report on Monday, September 18th. HC Wainwright set a $6.00 price target on shares of Can Fite Biopharma and gave the company a “buy” rating in a research report on Thursday, August 10th.

Shares of Can Fite Biopharma (NASDAQ:CANF) traded up 0.60% during midday trading on Monday, reaching $1.69. 15,516 shares of the company’s stock traded hands. The stock has a 50 day moving average of $1.69 and a 200-day moving average of $1.78. The stock’s market cap is $29.34 million. Can Fite Biopharma has a 12 month low of $1.50 and a 12 month high of $2.68.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/analysts-expect-can-fite-biopharma-ltd-canf-to-announce-0-14-earnings-per-share/1610928.html.

Can Fite Biopharma Company Profile

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Get a free copy of the Zacks research report on Can Fite Biopharma (CANF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.